江苏吴中(600200) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥440,798,793.24, an increase of 9.46% compared to the same period last year[2] - Net profit attributable to shareholders for the year-to-date period was ¥45,080,649.81, reflecting a significant increase of 311.54% year-on-year[2] - Basic earnings per share for Q3 2024 was ¥0.029, while year-to-date basic earnings per share was ¥0.063, up 320.00% compared to the previous year[3] - Total operating revenue for the first three quarters of 2024 reached ¥1,647,310,403.02, an increase of 9.6% compared to ¥1,503,350,988.42 in the same period of 2023[14] - Net profit for the first three quarters of 2024 was ¥47,123,827.54, compared to ¥9,462,674.19 in 2023, marking a significant increase[15] - Earnings per share for the first three quarters of 2024 were ¥0.063, up from ¥0.015 in the same period last year[15] - The total comprehensive income for the first three quarters of 2024 was ¥46,500,837.12, compared to ¥8,900,010.33 in 2023, showing a substantial improvement[15] Assets and Liabilities - Total assets as of the end of the reporting period were ¥4,126,657,408.30, a decrease of 4.63% from the end of the previous year[3] - As of September 30, 2024, the company's total assets amounted to RMB 4,126,657,408.30, a decrease from RMB 4,326,878,114.57 at the end of 2023, reflecting a decline of approximately 4.6%[10] - The company's current assets totaled RMB 2,932,207,712.94, down from RMB 3,001,217,681.76, indicating a decrease of about 2.3%[10] - The total liabilities decreased to ¥2,268,978,115.83 from ¥2,565,434,062.87, indicating a reduction of approximately 11.6%[12] - The total current liabilities decreased to RMB 1,956,004,706.17 from RMB 2,378,982,227.46, indicating a reduction of about 17.7%[11] Cash Flow - The company reported a net cash flow from operating activities of -¥149,943,597.45 for the year-to-date period[2] - In the first three quarters of 2024, the cash inflow from operating activities was CNY 5,367,387,229.59, a decrease of 2.4% compared to CNY 5,499,809,467.27 in the same period of 2023[17] - The net cash flow from operating activities was -CNY 149,943,597.45, an improvement from -CNY 286,526,275.97 in the first three quarters of 2023[17] - The total cash inflow from investment activities was CNY 13,345,793.13, significantly down from CNY 436,471,110.64 in the previous year[19] - The net cash flow from investment activities was -CNY 159,629,451.67, compared to a positive CNY 289,174,936.02 in the same period of 2023[19] - The cash inflow from financing activities was CNY 1,874,860,374.81, slightly down from CNY 1,877,366,267.57 in the previous year[19] - The net cash flow from financing activities was CNY 23,992,991.65, a decrease from CNY 195,463,746.06 in the first three quarters of 2023[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,629[7] - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 17.24% of the shares, with 104,100,000 shares pledged[7] Expenses - Total operating costs for the same period were ¥1,616,919,754.52, up from ¥1,521,393,157.99, reflecting a year-over-year increase of 6.3%[14] - Research and development expenses increased to ¥31,291,202.96 in 2024 from ¥27,791,579.74 in 2023, representing a growth of 18%[14] - The company reported a significant increase in sales expenses, which rose to ¥348,441,782.72 from ¥273,324,278.12, an increase of 27.5%[14] - The cash paid to employees increased to CNY 146,296,078.75 from CNY 128,522,354.98 in the same period of 2023[17] - The company reported a cash outflow of CNY 360,291,421.62 for other operating activities, slightly up from CNY 344,443,279.17 in the previous year[17] Government Support - Government subsidies recognized in the current period amounted to ¥6,025,071.24, contributing to the overall financial performance[4] Product and Market Development - The company has not indicated any new product launches or significant market expansion strategies during this reporting period[9] - The company’s medical beauty sector, particularly the AestheFill product, began generating profits from April 2024[5]